NM SB130

Prohibits cost sharing (copayments, coinsurance, deductibles) on generic cholesterol-lowering medications for group health coverage, individual health insurance, HMOs, and Medicaid

Eliminates cost sharing on second-line step therapy medications when generic drugs fail to lower cholesterol below 60 mg/dL or cause adverse reactions not tolerated by the patient

Removes cost sharing for coronary artery calcium screenings for eligible insureds over age 49, unless they have a strong family history of coronary artery disease or diagnosed symptoms

Expands cholesterol lipid panel coverage to include tests for total cholesterol, LDL, HDL, lipoprotein (a), triglycerides, and high-sensitivity c-reactive protein

Grants the Board of Pharmacy authority to establish protocols for assessing cardiovascular risk and prescribing lipid-lowering or cardiovascular plaque-reducing drug therapies based on risk levels